APEIRON Biologics APN01 selected for large-scale US trial in COVID-19
DGAP-News: APEIRON Biologics AG / Key word(s): Study
19.05.2021 / 09:00
APEIRON Biologics APN01 selected for large-scale US trial
in COVID-19
APEIRON s APN01 to participate in US Phase 2 COVID-19 trial ACTIV-4d RAAS
Further clinical study in preparation with inhalative drug delivery of APN01 to directly target respiratory tract and lung tissue
Additional pre-clinical data show highly promising results with APN01 in various mutation variants
Financing round planned to secure funding of further upcoming development steps
Vienna, Austria, 19 May 2021: APEIRON Biologics AG announced today the next development steps for APN01 (alunacedase alfa) for the treatment of COVID-19. Based on the recently announced clinical results from APEIRON s Phase 2 trial with APN01 in COVID-19, APN01 will be developed in further international clinical trials with different COVID-19 patient populations and drug delivery rou
Former West Bengal Chief Minister and eminent Left Front leader Buddhadeb Bhattacharya, who has been suffering from Chronic Obstructive Pulmonary Disease (COPD) for the last few days and his wife Mira Bhattacharya have tested positive for Covid .
APEIRON Biologics AG: APEIRON Biologics APN01 Selected for Large-Scale US Trial in COVID-19
APEIRON s APN01 to participate in US Phase 2 COVID-19 trial ACTIV-4d RAAS
Further clinical study in preparation with inhalative drug delivery of APN01 to directly target respiratory tract and lung tissue
Additional pre-clinical data show highly promising results with APN01 in various mutation variants
Financing round planned to secure funding of further upcoming development steps
VIENNA, AUSTRIA / ACCESSWIRE / May 19, 2021 / APEIRON Biologics AG announced today the next development steps for APN01 (alunacedase alfa) for the treatment of COVID-19. Based on the recently announced clinical results from APEIRON s Phase 2 trial with APN01 in COVID-19, APN01 will be developed in further international clinical trials with different COVID-19 patient populations and drug delivery routes.
Insmed Presents Broad Range of Data Across Its Three Programs at the American Thoracic Society 2021 International Conference
-Retrospective analysis of patients with COPD and NTM lung disease demonstrates statistically significantly higher mortality compared to patients with COPD without NTM lung disease-
-Post-hoc analysis from ARIKAYCE® (amikacin liposome inhalation suspension) clinical trials supports favorable benefit and safety profile, with a low number needed to treat (NNT) and high number needed to harm (NNH)-
News provided by
Share this article
Share this article
BRIDGEWATER, N.J., May 19, 2021 /PRNewswire/ Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported data from a total of nine posters and oral presentations across its three programs ARIKAYCE, brensocatib, and treprostinil palmitil inhalation powder (TPIP) at the virtual American Thoracic Society (A
Sex Differences in COPD Symptoms Predict Cardiac Comorbidity medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.